Bispecific Antibody Format Patents: Leaders & White Space 2026
- One assignee holds the bulk of the filings. 63 of the 93 records in scope trace to a single leader, with the rest spread thin down to single-digit and single-filing entrants.
- C07K peptide/protein claims dominate the field. 97.8% of the 93 records carry a C07K class, and 37.6% pair it with an A61K medicinal-preparation claim — format and formulation are filed together far more often than apart.
- Filing activity has pulled back sharply since 2021. The three-year run from 2021 to 2024 shows a 100% drop in filings, though 2025-2026 counts are still filling in as publications lag behind filing dates.
Filing growth compares 2021 (3 records) with 2024 (0) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this landscape covers
Bispecific antibody format engineering covers the structural fixes that let a single antibody bind two distinct targets without losing the stability or manufacturability of a native immunoglobulin: knob-into-hole heavy-chain pairing, correct light-chain pairing, valency control across two, three or four binding arms, and the half-life and immunogenicity trade-offs that come with each fix. The search set here is narrow by design — it isolates records that discuss chain pairing, knob-into-hole, valency, half-life, immunogenicity or format screening inside a bispecific or T-cell-engager format claim, rather than every antibody-engineering filing in general.
93 records fall inside that scope across the 2015-2026 window. The most-cited documents in the set are the earliest ones — native-immunoglobulin-format bispecifics filed and published before the rest of the field caught up — which is a normal citation pattern inside a searched corpus and says more about age than about current relevance.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 93-record set: how filing activity has moved year over year, and which IPC subclasses those filings actually sit under.
Filing trend, 2017-2026
Filings peaked at 3 in 2018 and ran near that level through the early 2020s. The 2021-to-2024 span shows a 100% decline, but 2025 and 2026 are undercounted because publication typically lags filing by around 18 months, so the true recent trend is not yet visible in this data.
IPC subclass distribution (of 93 records)
C07K (peptides and proteins) covers 97.8% of records, confirming this is overwhelmingly a molecular-structure field rather than a delivery or diagnostic one. A61K (medicinal preparations) appears in 37.6%, and the therapeutic-activity, microorganism-engineering and fermentation classes each sit in the single digits — format claims are filed far more often than the downstream production or use claims that follow them.
Shares are the percentage of the 93 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Bispecific Antibody Format Engineering with Eureka
This page is one run against one query. Ask Eureka your own question about bispecific antibody format engineering and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited documents in this set
EP2050764A1 — Polyvalent bispecific antibody format
The filing describes a polyvalent bispecific antibody format built from a first polypeptide carrying a constant heavy chain attached to two or more heavy-chain variable domains, and a second polypeptide carrying a constant light chain attached to two or more light-chain variable domains. A preferred embodiment is a tetravalent bispecific tandem immunoglobulin (TBTI). The claimed architecture keeps the stability profile of a native immunoglobulin by expressing the heavy and light chains on two separate polypeptides.Filed by Sanofi-Aventis, published 2009-04-22.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20100331527A1 | Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format | 876 |
| 2 | US8586713B2 | Readily isolated bispecific antibodies with native immunoglobulin format | 796 |
| 3 | WO2010151792A1 | Readily isolated bispecific antibodies with native immunoglobulin format | 539 |
| 4 | EP2050764A1 | Novel polyvalent bispecific antibody format and uses thereof | 237 |
| 5 | WO2015048272A1 | V-c-fc-v-c antibody | 233 |
| 6 | JP2012531439A | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 | 102 |
| 7 | WO2013072523A1 | BI-specific antibodies for medical use | 20 |
| 8 | US20160251395A1 | Readily isolated bispecific antibodies with native immunoglobulin format | 19 |
| 9 | WO2014076292A1 | Recombinant bispecific antibody binding to CD20 and CD95 | 18 |
| 10 | US20160257748A1 | V-c-fc-v-c antibody | 16 |
Citation counts reflect age as much as importance inside a searched corpus — the earliest native-immunoglobulin-format filings have had the longest window to accumulate citations.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data actually indicates
Three readings from the filing trend, the technology mix and the citation table, kept to what the evidence supports.
One assignee accounts for most of the activity
The ranked leader holds 63 records against a fifth-place assignee at 2 and a tenth-place assignee at 1. That gap between the top and the rest is a long tail of low-volume and single-filing entrants rather than a second cluster of active competitors.
Format claims sit almost entirely in one structural class
Nearly every record in scope carries a C07K classification, and over a third also carry A61K, meaning format claims are commonly bundled with a medicinal-preparation claim in the same filing rather than left as a standalone structural patent.
The oldest native-format filings still anchor the citation graph
The five most-cited records are early native-immunoglobulin-format bispecifics; their citation counts reflect the length of time they have been in the corpus, not that the underlying architecture is still the most active area of new filing.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bispecific antibody format engineering, with the prior art for and against each one.
Who is filing, and where the gaps sit
The ranking covers 11 companies and individual filers, counted in records — it is the complete list the dataset returns, not a top-50 or top-100 cut.
A single assignee dominates by volume
The top-ranked assignee's record count dwarfs every other entrant in the ranking, consistent with a company that has built a broad format-claim portfolio around chain pairing and valency rather than one that filed a single defensive patent.
Recent-year activity has thinned across the board
In the most recent year tracked, the ranked leader shows 1 filing and the other named assignees in the momentum data show 0. That pattern is consistent with the broader 2021-2024 decline, though the newest years remain undercounted.
Co-filing is sparse and mostly inventor-linked
The ten identified co-assignee pairs are dominated by individual-inventor combinations rather than company-to-company joint filings, suggesting most format IP in this set was developed and filed within a single organisation.
| Assignee | Recent year | YoY |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 1 | — |
| Baliopharm AG | 0 | — |
| Amgen Inc. | 0 | — |
| JUNG GUNDRAM | 0 | — |
| Sanofi SA | 0 | — |
| Sanofi-Aventis SA | 0 | — |
| GROSSE HOVEST LUDGER | 0 | — |
| CentryMed Pharma Inc. | 0 | — |
Where to take this from here
The landscape shows concentration at the top and thin activity everywhere else. What a team does with that depends on whether it is defending, designing around, or scouting for open ground.
Map claim boundaries before committing to a format
Chain-pairing and valency claims from the leading assignee are broad enough that a new tetravalent or trivalent design should be checked against them before formulation work starts.
Explore format claims in EurekaTrack the momentum data past this cut-off
Because 2025-2026 filings are still publishing, a fresh pull in six to twelve months will show whether the 2021-2024 decline continues or reverses.
Set up monitoring in EurekaTest the under-claimed branches for freedom to operate
Half-life extension and immunogenicity-reduction linker claims show lower density than core pairing claims, making them a reasonable first stop for a design-around search.
Run a white-space search in EurekaFrequently asked questions
Within this 93-record dataset, one assignee holds the great majority of filings at 63 records, far ahead of the next-ranked entrants which fall to single digits. That concentration means most of the chain-pairing and valency claim space filed since 2015 sits with one company's portfolio rather than being spread across several active competitors. Anyone designing a new format should check that leader's claims first, since a broad early filing there is more likely to constrain new work than any of the smaller entrants in the ranking.
Knob-into-hole mutations force two different heavy chains to pair correctly with each other rather than forming unwanted homodimers, which is one of the core manufacturability problems in any asymmetric bispecific design. In this dataset it appears alongside valency, half-life and immunogenicity as one of the recurring technical routes claimed in format patents. It does not by itself solve light-chain mispairing, which is why many filings in this set combine it with separate chain-pairing fixes.
C07K covers peptides and proteins, and 97.8% of the 93 records in scope carry that classification because a bispecific antibody format claim is fundamentally a molecular-structure claim. The next most common class, A61K for medicinal preparations, appears in 37.6% of records, showing that a large minority of filings pair the structural claim with a formulation claim in the same document. Because a single record can carry several IPC classes, these shares add up to more than 100% and should not be read as mutually exclusive categories.
The data shows a 100% decline in filings between 2021 and 2024, which is the most recent three-year span that can be treated as complete. However, publication typically lags actual filing by around 18 months, so the 2025 and 2026 counts in this dataset are still filling in and should not yet be read as continuing the decline. A meaningful read on the current trajectory will need another data pull once those years mature.
Relative to the dense core of chain-pairing and valency claims, sub-areas such as half-life extension modules for tetravalent formats, immunogenicity-reduction linker design, and format-screening assays for pairing fidelity show comparatively low filing density in this dataset. That does not guarantee those areas are unclaimed elsewhere, but within this scope they are less occupied than the core structural claims. A freedom-to-operate search focused on those specific branches is a reasonable starting point before committing to a new format design.
Research Bispecific Antibody Format Engineering in depth with Eureka
Go past this page: query the whole bispecific antibody format engineering corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.